Avanos Medical, Inc. (AVNS) — Fair Value Analysis

Base-case fair value (P50): $33.87 · Current price: $24.93 · Verdict: Undervalued

The Verdict on AVNS

Based on our Monte Carlo simulations, AVANOS MEDICAL INC (AVNS) appears Deeply Undervalued. Our analysis indicates a median fair value (P50) of $33.87, which represents a substantial +35.9% upside from the current trading price of $24.93. This significant discrepancy suggests that the market may be overlooking the underlying intrinsic value of AVNS, despite its current valuation. Investors reviewing AVNS at $24.93 should note the robust potential indicated by our model.

How AVNS stacks up against peers

AVNS demonstrates an average quality tier, reflecting its operational and financial health relative to its sector (n/a). While not a top-tier performer in terms of overall quality, its current undervaluation highlighted by the $33.87 fair value against $24.93 suggests a compelling risk-reward profile. The Monte Carlo analysis, which factors in thousands of forward-looking scenarios, consistently places AVNS's fair value significantly above its current market price, underpinning the +35.9% projected upside. This makes AVNS a noteworthy candidate for investors seeking value opportunities.

What this means for investors

The pronounced difference between AVNS’s current price of $24.93 and its median fair value of $33.87 points to a strong potential for capital appreciation. For investors, this translates into a Deeply Undervalued stock with a +35.9% implied upside, even considering its average quality tier. While a downside scenario is always possible in any investment, the probabilistic outcomes from our Monte Carlo model tilt heavily towards a positive re-rating. FairCurve offers a clear perspective on these dynamics. Sign up for FairCurve to see the full bear/bull distribution and track AVNS's fair value as new fundamentals are released.